An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease.
Hanxue ZhaoPeiyun LiHong-Liang ZhangLinpei JiaPublished in: Renal failure (2023)
HIF-PHIs may be a convenient and safe alternative to ESAs in patients with NDD-CKD and anemia.